Skip to main content

ImmunoGen, Inc.

IMGNDelisted Feb 12, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0000855654

ImmunoGen, Inc. was delisted on Feb 12, 2024; its insiders filed their last Form 4 on Feb 12, 2024; 327 institutions reported holding it in 13F filings for Q4 2023, worth $7.54B in total; Maverick Capital was the only superinvestor holding it.

13F holders, Q1 2021

Institutional positions in ImmunoGen, Inc. as of Mar 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
217
No complete 13F data for Q4 2020
Shares held
182.7M
No complete 13F data for Q4 2020
Total value
$1.48B
No complete 13F data for Q4 2020

Holders and value by quarter

Institutions reporting IMGN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2021: 217 institutions
Q1 2021: 217 institutionsQ2 2021: 214 institutionsQ3 2021: 217 institutionsQ4 2021: 236 institutionsQ1 2022: 217 institutionsQ2 2022: 216 institutionsQ3 2022: 222 institutionsQ4 2022: 204 institutionsQ1 2023: 191 institutionsQ2 2023: 266 institutionsQ3 2023: 276 institutionsQ4 2023: 327 institutionsQ1 2024: 3 institutionsQ2 2024: 1 institutionQ3 2024: 1 institutionQ4 2024: 1 institutionQ1 2025: 1 institutionQ2 2025: 1 institutionQ3 2025: 1 institutionQ4 2025: 1 institutionQ1 2026: 1 institutionQ2 2026: 1 institution
Value heldQ1 2021: $1.48B
Q1 2021: $1.48BQ2 2021: $1.19BQ3 2021: $1.00BQ4 2021: $1.41BQ1 2022: $925.0MQ2 2022: $882.4MQ3 2022: $942.2MQ4 2022: $1.01BQ1 2023: $806.0MQ2 2023: $4.24BQ3 2023: $3.91BQ4 2023: $7.54BQ1 2024: $27.8KQ2 2024: $31Q3 2024: $269Q4 2024: $269Q1 2025: $269Q2 2025: $269Q3 2025: $269Q4 2025: $269Q1 2026: $269Q2 2026: $269
Institutions holding IMGN and their total value by quarter
QuarterHoldersValue
Q2 20261$269
Q1 20261$269
Q4 20251$269
Q3 20251$269
Q2 20251$269
Q1 20251$269
Q4 20241$269
Q3 20241$269
Q2 20241$31
Q1 20243$27.8K
Q4 2023327$7.54B
Q3 2023276$3.91B
Q2 2023266$4.24B
Q1 2023191$806.0M
Q4 2022204$1.01B
Q3 2022222$942.2M
Q2 2022216$882.4M
Q1 2022217$925.0M
Q4 2021236$1.41B
Q3 2021217$1.00B
Q2 2021214$1.19B
Q1 2021217$1.48B

Institutions, Q1 2021

Shares, value and share of portfolio for each institution holding ImmunoGen, Inc..

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.

Institutions holding IMGN in Q1 2021
InstitutionSharesValue% of portfolioChange in sharesAction
Goldman Sachs Group Inc2,595,999$21.0M0.01%––
Two Sigma Advisers, LP2,947,918$23.9M0.07%––
Deutsche Bank AG2,994,172$24.3M0.01%––
Geode Capital Management, LLC3,516,791$28.5M0.00%––
Morgan Stanley4,203,979$34.1M0.01%––
Adage Capital Partners GP, L.L.C.4,500,000$36.5M0.07%––
Ameriprise Financial Inc5,595,683$45.3M0.02%––
Clearbridge Investments, LLC6,108,685$49.5M0.04%––
State Street Corp9,023,479$73.1M0.00%––
OrbiMed Advisors LLC9,131,822$74.0M0.70%––
Redmile Group, LLC9,688,066$78.5M1.11%––
FMR LLC13,534,350$109.6M0.01%––
Vanguard Group Inc14,307,139$115.9M0.00%––
BlackRock Inc.16,305,586$132.1M0.00%––
Ra Capital Management, L.P.18,417,458$149.2M2.25%––
Wellington Management Group LLP19,003,480$153.9M0.03%––
FourThought Financial, LLC15––––